Latest News and Press Releases
Want to stay updated on the latest news?
-
Lundbecks partner Teva Pharmaceutical Industries Ltd. har i dag offentliggjort den vellykkede afslutning af ADAGIO, som er en fase III-undersøgelse, der er tilrettelagt for at påvise, at Azilect® 1...
-
Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect® 1 mg tablets can slow down...
-
H. Lundbeck A/S skal herved offentliggøre oplysninger om ledende medarbejderes og disses nærtståendes transaktioner med aktier i H. Lundbeck A/S og dertil knyttede værdipapirer,...
-
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the...
-
H. Lundbeck A/S skal herved offentliggøre oplysninger om ledende medarbejderes og disses nærtståendes transaktioner med aktier i H. Lundbeck A/S og dertil knyttede værdipapirer,...
-
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the...
-
Bestyrelsen for Lundbeck har udnyttet bemyndigelsen til at erhverve egne aktier for indtil 10%. I henhold til programmet ville Lundbeck købe egne aktier for et beløb på indtil DKK 6 mia.,...
-
Lundbeck's Supervisory Board has acted on its authorization to acquire up to 10% of its shares. Under the program Lundbeck was to buy own shares for an amount of up to DKK 6 billion, cf....
-
H. Lundbeck A/S skal herved offentliggøre oplysninger om ledende medarbejderes og disses nærtståendes transaktioner med aktier i H. Lundbeck A/S og dertil knyttede værdipapirer,...
-
H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the...